NCT03348670View on ClinicalTrials.gov

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

May 18, 2026

Study Completion Date

May 28, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone - Usual

"* Oral~* Abiraterone Combined Chemotherapy"

DRUG

Abiraterone - Study

"* Oral~* Abiraterone Combined Chemotherapy"

Trial Locations (1)

20853

Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701, Rockville

All Listed Sponsors
lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY

NCT03348670 - Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms | Biotech Hunter | Biotech Hunter